A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA
Hematological Oncology - United Kingdom
doi 10.1002/hon.2632
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley